THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
At the Annual General Meeting of the Company held at 10.00 a.m. on 2 March 2020 at the offices of Orrick, Herrington & Sutcliffe (UK) LLP, 107 Cheapside, London, EC2V 6DN, all of the resolutions were duly passed.
The results of the proxy voting will be available shortly on the Company’s website, www.okyopharma.com.
The person who arranged for the release of this announcement was Tiziano Lazzaretti, Chief Financial Officer.
About OKYO
OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.
Enquiries:
OKYO Pharma Limited | Willy Simon | +44 (0)20 7382 8300 |
Shore Capital Limited (Broker) | Antonio Bossi David Coaten | +44 (0)20 7601 6100 |
For further information, please visit the Company’s website at www.okyopharma.com.